In Brief: Eclipse Surgical Technologies
This article was originally published in The Gray Sheet
Eclipse Surgical Technologies: Results of a double-blinded, multicenter Phase II transmyocardial revascularization trial using the firm's Eclipse 2000 laser show that 86% of patients experienced an improvement in anginal symptoms of two class levels or better at three month follow-up, the firm reports. Six-month follow-up data from the trial will be submitted this summer in support of a premarket approval application for the device ("The Gray Sheet" March 31, I&W-8)...
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.